Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ORPN
- CUSIP: N/A
- Web: bioblastpharma.com
- Market Cap: $8 million
- Outstanding Shares: 16,711,000
- 50 Day Moving Avg: $0.60
- 200 Day Moving Avg: $0.60
- 52 Week Range: $0.41 - $1.87
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.28 per share
- Price / Book: 1.69
- EBIDTA: ($9,960,000.00)
- Return on Equity: -155.26%
- Return on Assets: -128.89%
- Current Ratio: 6.97%
- Quick Ratio: 6.97%
- Average Volume: 101,833 shs.
- Beta: -0.04
- Short Ratio: 0.94
Frequently Asked Questions for Bio Blast Pharma (NASDAQ:ORPN)
What is Bio Blast Pharma's stock symbol?
Bio Blast Pharma trades on the NASDAQ under the ticker symbol "ORPN."
How were Bio Blast Pharma's earnings last quarter?
Bio Blast Pharma Ltd. (NASDAQ:ORPN) issued its quarterly earnings results on Thursday, August, 25th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.05. During the same period in the prior year, the company earned ($0.26) earnings per share. View Bio Blast Pharma's Earnings History.
When will Bio Blast Pharma make its next earnings announcement?
Where is Bio Blast Pharma's stock going? Where will Bio Blast Pharma's stock price be in 2017?
1 analysts have issued 12 month price targets for Bio Blast Pharma's stock. Their forecasts range from $0.63 to $15.00. On average, they expect Bio Blast Pharma's share price to reach $7.82 in the next year. View Analyst Ratings for Bio Blast Pharma.
Who are some of Bio Blast Pharma's key competitors?
Some companies that are related to Bio Blast Pharma include Anthera Pharmaceuticals (ANTH), Celsion Corporation (CLSN), Evgen Pharma PLC (EVG), Proteome Sciences plc (PRM), Cerulean Pharma (DARE), Kitov Pharmaceuticals Holdings (KTOV), Ritter Pharmaceuticals (RTTR), Opexa Therapeutics (ACER), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX), Biotie Therapies Corp (BITI), Cynapsus Therapeutics (CYNA), Dyax Corp. (DYAX), Forward Pharma A/S (FWP), Kythera Biopharmaceuticals (KYTH), Medivation (MDVN) and MEI Pharma (MSHL).
How do I buy Bio Blast Pharma stock?
Shares of Bio Blast Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio Blast Pharma's stock price today?
MarketBeat Community Rating for Bio Blast Pharma (NASDAQ ORPN)MarketBeat's community ratings are surveys of what our community members think about Bio Blast Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Bio Blast Pharma stock can currently be purchased for approximately $0.48.
Consensus Ratings for Bio Blast Pharma (NASDAQ:ORPN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$7.82 (1,532.89% upside)|
Analysts' Ratings History for Bio Blast Pharma (NASDAQ:ORPN)
(Data available from 9/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/28/2017||S&P Equity Research||Boost Price Target||$0.56 -> $0.63||Low|
|10/24/2016||Roth Capital||Set Price Target||Buy||$15.00||N/A|
|7/11/2016||Rodman & Renshaw||Reiterated Rating||Buy||N/A|
|1/28/2016||HC Wainwright||Initiated Coverage||Buy||$25.00||N/A|
|11/27/2015||Oppenheimer Holdings, Inc.||Reiterated Rating||Outperform||$32.00||N/A|
Earnings History for Bio Blast Pharma (NASDAQ:ORPN)Earnings History by Quarter for Bio Blast Pharma (NASDAQ ORPN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Bio Blast Pharma (NASDAQ:ORPN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Bio Blast Pharma (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Bio Blast Pharma (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Bio Blast Pharma (NASDAQ:ORPN)
Latest Headlines for Bio Blast Pharma (NASDAQ:ORPN)
Bio Blast Pharma (ORPN) Chart for Sunday, September, 24, 2017